Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Current Deferred Revenue (2022 - 2025)

Abvc Biopharma (ABVC) has disclosed Current Deferred Revenue for 4 consecutive years, with $12600.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 84.47% year-over-year to $12600.0, compared with a TTM value of $12600.0 through Dec 2025, down 84.47%, and an annual FY2025 reading of $12600.0, down 84.47% over the prior year.
  • Current Deferred Revenue was $12600.0 for Q4 2025 at Abvc Biopharma, down from $81115.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $81115.0 in Q4 2024 and bottomed at $10985.0 in Q4 2022.
  • Average Current Deferred Revenue over 4 years is $68753.9, with a median of $79500.5 recorded in 2023.
  • The sharpest move saw Current Deferred Revenue surged 623.71% in 2023, then tumbled 84.47% in 2025.
  • Year by year, Current Deferred Revenue stood at $10985.0 in 2022, then soared by 623.71% to $79500.0 in 2023, then grew by 2.03% to $81115.0 in 2024, then crashed by 84.47% to $12600.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for ABVC at $12600.0 in Q4 2025, $81115.0 in Q3 2025, and $81115.0 in Q2 2025.